SIMILAR PATTERNS OF AMINO ACIDS FOR 3SXR_A_1N1A1_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 416 ALA A 428 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.51A	3sxrA-1k2pA: 32.7	3sxrA-1k2pA: 65.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	VAL A 209 ALA A 220 MET A 240 VAL A 249 ILE A 264 THR A 266 TYR A 268 GLY A 272 LEU A 321	None	0.52A	3sxrA-1k9aA: 32.1	3sxrA-1k9aA: 29.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 267 VAL A 275 ALA A 288 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.62A	3sxrA-1opkA: 33.1	3sxrA-1opkA: 25.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 ALA A 642 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	0.52A	3sxrA-1rjbA: 29.1	3sxrA-1rjbA: 36.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 78 VAL A 86 ALA A 99 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.48A	3sxrA-1s9iA: 21.9	3sxrA-1s9iA: 24.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 595 VAL A 603 ALA A 621 VAL A 654 THR A 670 TYR A 672 GLY A 676 LEU A 799	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-4.3A) STI A 3 (-3.2A) STI A 3 ( 4.0A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.56A	3sxrA-1t46A: 30.0	3sxrA-1t46A: 35.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 344 VAL A 352 ALA A 367 MET A 390 VAL A 399 GLY A 420 LEU A 468	STU A 100 (-3.8A) STU A 100 (-4.8A) STU A 100 (-3.2A) None None STU A 100 (-3.5A) STU A 100 (-4.5A)	0.48A	3sxrA-1u59A: 32.1	3sxrA-1u59A: 37.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 VAL A 68 TYR A 86 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-4.8A) HYM A 400 (-4.7A) None HYM A 400 (-4.5A)	0.53A	3sxrA-1zltA: 23.7	3sxrA-1zltA: 26.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zy4	SERINE/THREONINE-PRO TEIN KINASE GCN2 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 605 VAL A 613 ALA A 626 VAL A 656 ILE A 786 TYR A 790	None None GOL A 998 ( 3.7A) GOL A 998 (-4.9A) None GOL A 998 (-4.6A)	0.40A	3sxrA-1zy4A: 20.0	3sxrA-1zy4A: 27.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU X 17 VAL X 25 ALA X 37 MET X 58 VAL X 67 ILE X 80 THR X 82 TYR X 84 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) None None None STU X 902 (-4.1A) STU X 902 (-4.6A) STU X 902 (-3.5A) STU X 902 (-4.4A)	0.53A	3sxrA-2dq7X: 34.2	3sxrA-2dq7X: 41.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 VAL A 323 ILE A 336 THR A 338 TYR A 340 GLY A 344 LEU A 393	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) None H8H A 534 ( 4.5A) H8H A 534 (-3.1A) H8H A 534 (-4.3A) H8H A 534 (-3.3A) H8H A 534 (-4.5A)	0.47A	3sxrA-2h8hA: 30.8	3sxrA-2h8hA: 24.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 VAL A 323 ILE A 336 THR A 338 GLY A 344 LEU A 393	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 (-4.4A)	0.61A	3sxrA-2hckA: 30.6	3sxrA-2hckA: 32.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 643 ALA A 659 MET A 682 ILE A 705 THR A 707 GLY A 713 LEU A 761	ADP A 400 ( 4.4A) ADP A 400 (-3.2A) None None ADP A 400 (-4.7A) ADP A 400 ( 4.2A) ADP A 400 ( 4.7A)	0.66A	3sxrA-2henA: 31.6	3sxrA-2henA: 36.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 251 VAL A 259 ALA A 271 MET A 292 VAL A 301 ILE A 314 THR A 316 GLY A 322 LEU A 371	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 ( 3.8A) None 1BM A 499 (-3.9A) 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) 1BM A 499 (-4.4A)	0.47A	3sxrA-2hk5A: 34.7	3sxrA-2hk5A: 41.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 248 VAL A 256 ALA A 269 MET A 290 VAL A 299 ILE A 313 THR A 315 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.2A) GIN A 600 (-4.6A) GIN A 600 (-3.8A) GIN A 600 (-3.4A) None GIN A 600 (-4.7A)	0.65A	3sxrA-2hz0A: 32.2	3sxrA-2hz0A: 41.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	7	VAL A 436 ALA A 452 MET A 475 VAL A 484 ILE A 497 GLY A 505 LEU A 553	4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) None None None 4ST A1687 (-3.2A) 4ST A1687 (-4.4A)	0.62A	3sxrA-2j0jA: 31.2	3sxrA-2j0jA: 18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	VAL A 436 ALA A 452 MET A 475 VAL A 484 ILE A 497 GLY A 505 LEU A 553	BII A1687 ( 4.7A) BII A1687 (-3.5A) None None None BII A1687 (-3.6A) BII A1687 (-4.2A)	0.55A	3sxrA-2jkmA: 31.4	3sxrA-2jkmA: 37.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 271 MET A 292 VAL A 301 ILE A 314 THR A 316 TYR A 318 GLY A 322 LEU A 371	1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) None 1N8 A 501 ( 4.6A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.58A	3sxrA-2og8A: 31.0	3sxrA-2og8A: 44.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 VAL A 259 ALA A 271 MET A 292 VAL A 301 ILE A 314 THR A 316 TYR A 318	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) None 1N8 A 501 ( 4.6A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A)	0.52A	3sxrA-2og8A: 31.0	3sxrA-2og8A: 44.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 ALA A 614 MET A 637 VAL A 647 THR A 663 TYR A 665 LEU A 785	None	0.59A	3sxrA-2ogvA: 28.2	3sxrA-2ogvA: 35.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 ALA A 614 VAL A 647 THR A 663 TYR A 665 GLY A 669 LEU A 785	None	0.47A	3sxrA-2ogvA: 28.2	3sxrA-2ogvA: 35.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ALA A 515 MET A 538 TYR A 566 GLY A 570 LEU A 633	None	0.51A	3sxrA-2psqA: 32.1	3sxrA-2psqA: 31.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 MET A 674 ILE A 697 THR A 699 GLY A 705 LEU A 753	BME A 1 (-4.9A) PTR A 701 ( 4.7A) None None None None None	0.66A	3sxrA-2qobA: 32.1	3sxrA-2qobA: 32.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	8	VAL A 689 ALA A 705 MET A 728 ILE A 751 THR A 753 TYR A 755 GLY A 759 LEU A 807	None	0.53A	3sxrA-2r2pA: 33.6	3sxrA-2r2pA: 35.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 724 VAL A 732 ALA A 749 VAL A 781 THR A 796 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 ( 4.7A) GW7 A 1 (-4.0A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.68A	3sxrA-2r4bA: 29.3	3sxrA-2r4bA: 33.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	8	VAL A 635 ALA A 651 MET A 674 ILE A 697 THR A 699 TYR A 701 GLY A 705 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-3.9A) Q9G A1898 ( 4.6A) Q9G A1898 (-3.5A) Q9G A1898 (-4.8A) Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.53A	3sxrA-2xyuA: 32.1	3sxrA-2xyuA: 37.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 MET A 674 ILE A 697 THR A 699 TYR A 701 SER A 763	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-3.9A) Q9G A1898 ( 4.6A) Q9G A1898 (-3.5A) Q9G A1898 (-4.8A) Q9G A1898 (-3.2A)	0.65A	3sxrA-2xyuA: 32.1	3sxrA-2xyuA: 37.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1002 VAL A1010 ALA A1028 MET A1051 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None S91 A 1 (-3.3A)	0.37A	3sxrA-2z8cA: 30.6	3sxrA-2z8cA: 37.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	9	LEU A 253 VAL A 261 ALA A 273 MET A 294 VAL A 303 ILE A 317 THR A 319 GLY A 325 LEU A 374	None	0.63A	3sxrA-2zv7A: 33.9	3sxrA-2zv7A: 43.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ALA A 515 MET A 538 TYR A 566 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None M33 A1996 ( 4.7A) M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.30A	3sxrA-3b2tA: 31.9	3sxrA-3b2tA: 36.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 209 ALA A 220 MET A 240 VAL A 249 ILE A 264 THR A 266 TYR A 268 GLY A 272 LEU A 321	None	0.53A	3sxrA-3d7uA: 32.8	3sxrA-3d7uA: 42.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 431 VAL A 439 ALA A 455 VAL A 487 ILE A 500 GLY A 508 LEU A 556	AGS A 999 ( 4.4A) AGS A 999 (-4.6A) AGS A 999 (-3.6A) None None None AGS A 999 (-4.5A)	0.68A	3sxrA-3fzpA: 30.8	3sxrA-3fzpA: 37.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 833 VAL A 841 ALA A 859 VAL A 892 TYR A 911 GLY A 915 LEU A1029	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 ( 4.7A) 8ST A2001 (-4.9A) None None	0.64A	3sxrA-3hngA: 29.0	3sxrA-3hngA: 33.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 696 VAL A 704 VAL A 753 THR A 768 TYR A 770 GLY A 774 LEU A 822	ANP A 1 (-4.4A) ANP A 1 (-3.9A) None ANP A 1 ( 4.8A) ANP A 1 (-4.3A) ANP A 1 ( 4.9A) ANP A 1 (-4.7A)	0.48A	3sxrA-3kexA: 27.6	3sxrA-3kexA: 31.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 ILE A 711 THR A 713 TYR A 715 GLY A 719 LEU A 767	None None None None GOL A 403 (-4.1A) GOL A 403 (-3.4A) None	0.64A	3sxrA-3kulA: 33.8	3sxrA-3kulA: 35.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 MET A 688 THR A 713 TYR A 715 GLY A 719 LEU A 767	None None None None GOL A 403 (-4.1A) GOL A 403 (-3.4A) None	0.59A	3sxrA-3kulA: 33.8	3sxrA-3kulA: 35.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	VAL A 218 ALA A 229 THR A 279 TYR A 281 GLY A 285 LEU A 339	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) LDN A 1 (-3.8A) LDN A 1 ( 4.8A) LDN A 1 (-3.3A) LDN A 1 (-4.5A)	0.31A	3sxrA-3mdyA: 26.1	3sxrA-3mdyA: 27.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 88 VAL A 96 ALA A 109 MET A 134 TYR A 161 GLY A 165 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) None None None None	0.66A	3sxrA-3nuuA: 25.1	3sxrA-3nuuA: 26.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 726 VAL A 734 ALA A 751 THR A 798 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.1A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.43A	3sxrA-3pp0A: 30.8	3sxrA-3pp0A: 30.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	8	VAL A 565 ALA A 576 MET A 600 VAL A 609 THR A 625 TYR A 627 GLY A 631 LEU A 683	STU A 1 (-4.9A) STU A 1 (-3.3A) None None STU A 1 (-4.1A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 (-4.3A)	0.48A	3sxrA-3ppzA: 32.0	3sxrA-3ppzA: 34.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	8	VAL A 565 ALA A 576 VAL A 609 ILE A 623 THR A 625 TYR A 627 GLY A 631 LEU A 683	STU A 1 (-4.9A) STU A 1 (-3.3A) None None STU A 1 (-4.1A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 (-4.3A)	0.47A	3sxrA-3ppzA: 32.0	3sxrA-3ppzA: 34.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 345 MET A 388 THR A 413 TYR A 415 ILE A 416 GLY A 419 LEU A 467	STU A 1 (-3.8A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-4.3A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.61A	3sxrA-3s95A: 25.6	3sxrA-3s95A: 30.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	12	LEU A 423 VAL A 431 ALA A 443 MET A 464 VAL A 473 ILE A 487 THR A 489 TYR A 491 ILE A 492 GLY A 495 LEU A 543 SER A 553	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None PP2 A 1 (-3.6A) PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 (-4.1A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A) PP2 A 1 (-3.5A)	0.38A	3sxrA-3sxsA: 42.4	3sxrA-3sxsA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 MET A 535 TYR A 563 GLY A 567 LEU A 630	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-4.7A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A)	0.63A	3sxrA-3tt0A: 28.8	3sxrA-3tt0A: 31.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 544 VAL A 552 ALA A 570 VAL A 601 TYR A 619 GLY A 623 LEU A 686	0F4 A 902 ( 4.2A) None 0F4 A 902 (-3.2A) None 0F4 A 902 (-4.2A) 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.34A	3sxrA-3v5qA: 30.9	3sxrA-3v5qA: 37.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 75 VAL A 83 ALA A 96 VAL A 128 ILE A 142 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-4.2A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.52A	3sxrA-3wigA: 23.3	3sxrA-3wigA: 25.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 840 VAL A 848 ALA A 866 VAL A 899 GLY A 922 LEU A1035	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) None LEV A1201 (-3.6A) LEV A1201 (-4.8A)	0.38A	3sxrA-3wzdA: 29.8	3sxrA-3wzdA: 36.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1951 VAL A1959 ALA A1978 MET A2001 ILE A2024 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.80A	3sxrA-3zbfA: 25.2	3sxrA-3zbfA: 39.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 633 ALA A 649 MET A 672 ILE A 695 THR A 697 GLY A 703 LEU A 751	None	0.53A	3sxrA-3zfxA: 33.0	3sxrA-3zfxA: 38.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 83 VAL A 91 ALA A 104 TYR A 156 GLY A 160 LEU A 207	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) VX6 A 500 (-4.2A) VX6 A 500 (-3.3A) VX6 A 500 (-4.6A)	0.42A	3sxrA-4af3A: 20.8	3sxrA-4af3A: 23.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 560 VAL A 568 ALA A 586 VAL A 617 TYR A 635 GLY A 639 LEU A 699	LTI A1839 ( 4.2A) None LTI A1839 (-3.3A) None LTI A1839 (-4.7A) LTI A1839 (-3.4A) LTI A1839 (-4.2A)	0.43A	3sxrA-4at3A: 30.2	3sxrA-4at3A: 36.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 105 ALA A 121 MET A 144 ILE A 167 THR A 169 GLY A 175 LEU A 223	30K A1365 ( 4.6A) 30K A1365 (-3.2A) None None 30K A1365 (-3.8A) 30K A1365 (-3.5A) 30K A1365 (-4.5A)	0.47A	3sxrA-4aw5A: 32.1	3sxrA-4aw5A: 35.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 42 VAL A 50 ALA A 63 VAL A 94 ILE A 108 GLY A 116 LEU A 164	XZN A1317 (-3.6A) XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-4.4A) XZN A1317 (-4.4A) XZN A1317 ( 3.7A) XZN A1317 (-4.7A)	0.64A	3sxrA-4bc6A: 22.5	3sxrA-4bc6A: 29.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 663 VAL A 671 ALA A 684 VAL A 721 TYR A 739 GLY A 743 LEU A 789	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) None None None AGS A1985 (-4.8A)	0.48A	3sxrA-4crsA: 24.4	3sxrA-4crsA: 25.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 575 ALA A 588 VAL A 620 ILE A 634 GLY A 642 LEU A 690	GUI A 901 (-4.5A) GUI A 901 (-3.4A) None None GUI A 901 (-3.5A) GUI A 901 (-4.3A)	0.39A	3sxrA-4e93A: 33.6	3sxrA-4e93A: 37.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eqm	PROTEIN KINASE (Staphylococcus aureus)	PF00069 (Pkinase)	7	LEU A 16 VAL A 24 ALA A 37 VAL A 71 TYR A 89 ILE A 90 LEU A 140	ANP A 300 (-4.7A) ANP A 300 ( 4.7A) ANP A 300 ( 3.8A) None ANP A 300 (-4.3A) ANP A 300 (-4.8A) ANP A 300 (-4.7A)	0.64A	3sxrA-4eqmA: 23.4	3sxrA-4eqmA: 24.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 MET A 424 VAL A 433 GLY A 454 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) None None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A)	0.59A	3sxrA-4f4pA: 31.9	3sxrA-4f4pA: 38.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1122 VAL A1130 ALA A1148 VAL A1180 ILE A1194 GLY A1202 LEU A1256	0UV A1501 (-3.8A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 ( 4.9A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A)	0.44A	3sxrA-4fodA: 30.4	3sxrA-4fodA: 33.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 828 VAL A 836 ALA A 853 VAL A 884 TYR A 904 GLY A 908 LEU A 956	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) None 19S A1201 (-4.7A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A)	0.44A	3sxrA-4hviA: 30.9	3sxrA-4hviA: 32.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.40A	3sxrA-4hzsA: 16.7	3sxrA-4hzsA: 39.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.43A	3sxrA-4id7A: 33.1	3sxrA-4id7A: 39.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 VAL A 323 ILE A 336 TYR A 340 GLY A 344 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) None 0J9 A 601 (-4.4A) 0J9 A 601 ( 4.7A) 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A)	0.52A	3sxrA-4k11A: 30.4	3sxrA-4k11A: 29.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 478 VAL A 486 ALA A 506 MET A 529 TYR A 557 GLY A 561 LEU A 624	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) None None ACP A 801 ( 4.6A) ACP A 801 (-4.4A)	0.49A	3sxrA-4k33A: 32.6	3sxrA-4k33A: 34.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 33 VAL A 41 ALA A 54 MET A 74 VAL A 83 ILE A 97 TYR A 101 GLY A 105	GOL A 404 ( 3.6A) GOL A 404 (-4.5A) GOL A 404 ( 3.1A) None GOL A 403 (-4.1A) None GOL A 404 ( 4.9A) GOL A 404 (-3.6A)	0.54A	3sxrA-4lg4A: 25.4	3sxrA-4lg4A: 29.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 MET A 314 VAL A 323 ILE A 336 TYR A 340 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 ( 3.6A) VGG A 601 ( 4.8A) VGG A 601 (-4.2A) VGG A 601 ( 4.0A) VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.56A	3sxrA-4lggA: 29.3	3sxrA-4lggA: 43.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 46 ALA A 67 MET A 89 VAL A 99 THR A 123 GLY A 128 LEU A 180	SIN A 401 ( 3.9A) SIN A 401 ( 3.7A) None None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.77A	3sxrA-4o38A: 20.5	3sxrA-4o38A: 26.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 46 VAL A 54 ALA A 67 VAL A 99 THR A 123 GLY A 128 LEU A 180	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.47A	3sxrA-4o38A: 20.5	3sxrA-4o38A: 26.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 627 VAL A 635 ALA A 648 VAL A 685 TYR A 703 GLY A 707 LEU A 753	None	0.57A	3sxrA-4otdA: 25.1	3sxrA-4otdA: 26.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 627 ALA A 644 ILE A 690 THR A 692 TYR A 694 GLY A 698 LEU A 746	None	0.57A	3sxrA-4p2kA: 33.4	3sxrA-4p2kA: 38.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 627 ALA A 644 MET A 667 ILE A 690 THR A 692 TYR A 694 SER A 756	None	0.55A	3sxrA-4p2kA: 33.4	3sxrA-4p2kA: 38.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 ALA A 642 VAL A 675 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) None P30 A1001 (-4.1A) P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.38A	3sxrA-4rt7A: 30.2	3sxrA-4rt7A: 32.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	10	LEU A 14 VAL A 22 ALA A 35 MET A 56 VAL A 65 ILE A 79 THR A 81 TYR A 83 GLY A 87 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None None ACP A1264 (-4.5A) ACP A1264 ( 4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.53A	3sxrA-4ueuA: 33.7	3sxrA-4ueuA: 52.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 52 VAL A 60 ALA A 72 MET A 94 VAL A 104 GLY A 132 LEU A 183	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None None KSA A 405 (-3.5A) KSA A 405 (-4.6A)	0.60A	3sxrA-4wsqA: 24.8	3sxrA-4wsqA: 27.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 52 VAL A 60 ALA A 72 VAL A 104 ILE A 124 GLY A 132 LEU A 183	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None None KSA A 405 (-3.5A) KSA A 405 (-4.6A)	0.44A	3sxrA-4wsqA: 24.8	3sxrA-4wsqA: 27.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.57A	3sxrA-4xeyB: 33.4	3sxrA-4xeyB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	LEU B 267 VAL B 275 ALA B 288 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.44A	3sxrA-4xeyB: 33.4	3sxrA-4xeyB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.83A	3sxrA-4xi2A: 32.0	3sxrA-4xi2A: 43.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 SER A 538	None	0.69A	3sxrA-4xi2A: 32.0	3sxrA-4xi2A: 43.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 ALA A 642 VAL A 675 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.5A) None P30 A1001 ( 4.4A) P30 A1001 (-3.5A) P30 A1001 (-4.3A)	0.52A	3sxrA-4xufA: 29.7	3sxrA-4xufA: 39.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	9	LEU A 408 VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) None None 746 A 702 (-3.7A) 746 A 702 (-4.4A) 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.41A	3sxrA-4y93A: 32.9	3sxrA-4y93A: 40.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 477 ALA A 488 ILE A 537 THR A 539 TYR A 541 LEU A 595	None 4CV A 801 (-3.5A) None 4CV A 801 (-2.8A) 4CV A 801 (-3.9A) 4CV A 801 (-4.4A)	0.39A	3sxrA-4yffA: 26.0	3sxrA-4yffA: 27.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 MET A 535 TYR A 563 GLY A 567 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) EDO A1766 (-3.5A) 38O A1769 (-4.2A) 38O A1769 (-3.4A) 38O A1769 (-4.6A)	0.54A	3sxrA-5a46A: 29.1	3sxrA-5a46A: 32.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 VAL A 911 ALA A 928 TYR A 980 GLY A 984 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) 5U3 A1200 (-4.5A) 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A)	0.26A	3sxrA-5f1zA: 29.8	3sxrA-5f1zA: 33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 599 VAL A 607 ALA A 625 MET A 648 VAL A 658 THR A 674 TYR A 676 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-3.4A) 748 A1001 ( 4.8A) 748 A1001 (-3.2A) 748 A1001 (-4.0A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.65A	3sxrA-5grnA: 30.1	3sxrA-5grnA: 35.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 599 VAL A 607 ALA A 625 VAL A 658 ILE A 672 THR A 674 TYR A 676 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 ( 4.8A) 748 A1001 (-3.9A) 748 A1001 (-3.2A) 748 A1001 (-4.0A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.56A	3sxrA-5grnA: 30.1	3sxrA-5grnA: 35.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gz8	PROTEIN O-MANNOSE KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	8	VAL A 94 ALA A 105 VAL A 134 ILE A 146 THR A 148 TYR A 150 GLY A 154 LEU A 215	None	0.55A	3sxrA-5gz8A: 20.8	3sxrA-5gz8A: 25.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gza	PROTEIN O-MANNOSE KINASE (Danio rerio)	PF07714 (Pkinase_Tyr)	7	VAL A 93 ALA A 104 VAL A 133 THR A 147 TYR A 149 GLY A 153 LEU A 214	ADP A 401 (-4.4A) ADP A 401 (-3.2A) None ADP A 401 ( 4.8A) ADP A 401 ( 4.8A) ADP A 401 ( 4.1A) ADP A 401 (-4.4A)	0.45A	3sxrA-5gzaA: 20.3	3sxrA-5gzaA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 57 VAL A 65 ALA A 77 ILE A 128 TYR A 132 GLY A 136 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) None IDV A 401 (-3.5A) IDV A 401 (-3.4A) IDV A 401 (-4.4A)	0.39A	3sxrA-5i3oA: 24.7	3sxrA-5i3oA: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 57 VAL A 65 ALA A 77 MET A 99 VAL A 109 TYR A 132 GLY A 136 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) None None IDV A 401 (-3.5A) IDV A 401 (-3.4A) IDV A 401 (-4.4A)	0.46A	3sxrA-5i3oA: 24.7	3sxrA-5i3oA: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 30 ALA A 43 MET A 65 VAL A 74 ILE A 88 GLY A 96 LEU A 143	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None None None 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A)	0.56A	3sxrA-5j5tA: 22.8	3sxrA-5j5tA: 24.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 284 ALA A 297 MET A 319 VAL A 328 TYR A 346 GLY A 350 LEU A 396	IPW A 601 (-4.2A) IPW A 601 (-3.5A) IPW A 601 (-4.1A) None IPW A 601 (-4.5A) IPW A 601 ( 3.8A) IPW A 601 (-4.5A)	0.46A	3sxrA-5kbrA: 24.3	3sxrA-5kbrA: 30.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 49 ALA A 60 VAL A 94 TYR A 112 GLY A 116 LEU A 163	None STU A 901 (-3.3A) None STU A 901 (-4.6A) STU A 901 (-3.5A) STU A 901 (-4.5A)	0.38A	3sxrA-5lohA: 22.0	3sxrA-5lohA: 26.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vdk	WEE1-LIKE PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 226 ALA A 239 VAL A 273 ILE A 287 TYR A 291 GLY A 295	8X7 A 501 ( 4.5A) 8X7 A 501 ( 3.7A) 8X7 A 501 ( 4.6A) PO4 A 502 (-3.4A) 8X7 A 501 (-4.2A) 8X7 A 501 (-3.6A)	0.42A	3sxrA-5vdkA: 17.8	3sxrA-5vdkA: 20.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	8	LEU A 24 VAL A 32 ALA A 45 ILE A 93 THR A 95 TYR A 97 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.9A) 9WS A 401 (-3.2A) None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.49A	3sxrA-5w5jA: 24.0	3sxrA-5w5jA: 28.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	8	LEU A 891 VAL A 899 ALA A 917 ILE A 961 THR A 963 TYR A 965 GLY A 969 LEU A1017	ANP A1201 (-4.1A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) None ANP A1201 (-3.9A) ANP A1201 (-4.4A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A)	0.49A	3sxrA-5wnoA: 27.9	3sxrA-5wnoA: 14.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	8	LEU A 33 VAL A 41 ALA A 54 VAL A 83 ILE A 97 TYR A 101 GLY A 105 LEU A 153	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) None None ANP A 501 ( 4.2A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A)	0.56A	3sxrA-6ao5A: 23.0	3sxrA-6ao5A: 24.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	6	LEU A 881 VAL A 889 ALA A 906 VAL A 938 GLY A 962 LEU A1010	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.38A	3sxrA-6c7yA: 30.7	3sxrA-6c7yA: 15.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	7	LEU A 197 VAL A 205 ALA A 217 ILE A 262 THR A 264 GLY A 270 LEU A 319	FKY A9001 (-4.1A) FKY A9001 ( 4.6A) FKY A9001 (-3.3A) None FKY A9001 (-3.0A) FKY A9001 (-3.3A) FKY A9001 ( 4.9A)	0.66A	3sxrA-6cz4A: 30.1	3sxrA-6cz4A: 17.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	6	VAL A 200 ALA A 211 VAL A 246 TYR A 264 GLY A 268 LEU A 318	CJT A 502 ( 4.8A) CJT A 502 (-3.4A) None CJT A 502 (-4.5A) CJT A 502 ( 4.3A) CJT A 502 (-4.7A)	0.43A	3sxrA-6f3dA: 25.3	3sxrA-6f3dA: 17.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	6	LEU A 730 VAL A 738 ALA A 756 TYR A 806 GLY A 810 LEU A 881	ADN A1104 ( 4.0A) ADN A1104 (-4.4A) ADN A1104 (-3.4A) ADN A1104 ( 4.1A) ADN A1104 ( 3.8A) ADN A1104 (-4.3A)	0.40A	3sxrA-6fekA: 31.9	3sxrA-6fekA: 17.18

[["3SXR_A_1N1A1_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"VAL A 416;ALA A 428;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.51A","3sxrA-1k2pA:32.7","3sxrA-1k2pA:65.67"],["3SXR_A_1N1A1_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"VAL A 209;ALA A 220;MET A 240;VAL A 249;ILE A 264;THR A 266;TYR A 268;GLY A 272;LEU A 321","None","0.52A","3sxrA-1k9aA:32.1","3sxrA-1k9aA:29.03"],["3SXR_A_1N1A1_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 267;VAL A 275;ALA A 288;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.62A","3sxrA-1opkA:33.1","3sxrA-1opkA:25.71"],["3SXR_A_1N1A1_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","0.52A","3sxrA-1rjbA:29.1","3sxrA-1rjbA:36.07"],["3SXR_A_1N1A1_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",7,"LEU A  78;VAL A  86;ALA A  99;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.48A","3sxrA-1s9iA:21.9","3sxrA-1s9iA:24.79"],["3SXR_A_1N1A1_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",8,"LEU A 595;VAL A 603;ALA A 621;VAL A 654;THR A 670;TYR A 672;GLY A 676;LEU A 799","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-4.3A);STI A   3 (-3.2A);STI A   3 ( 4.0A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.56A","3sxrA-1t46A:30.0","3sxrA-1t46A:35.78"],["3SXR_A_1N1A1_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",7,"LEU A 344;VAL A 352;ALA A 367;MET A 390;VAL A 399;GLY A 420;LEU A 468","STU A 100 (-3.8A);STU A 100 (-4.8A);STU A 100 (-3.2A);None;None;STU A 100 (-3.5A);STU A 100 (-4.5A)","0.48A","3sxrA-1u59A:32.1","3sxrA-1u59A:37.88"],["3SXR_A_1N1A1_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;VAL A  68;TYR A  86;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-4.8A);HYM A 400 (-4.7A);None;HYM A 400 (-4.5A)","0.53A","3sxrA-1zltA:23.7","3sxrA-1zltA:26.86"],["3SXR_A_1N1A1_1","1zy4","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE GCN2","PF00069(Pkinase)",6,"LEU A 605;VAL A 613;ALA A 626;VAL A 656;ILE A 786;TYR A 790","None;None;GOL A 998 ( 3.7A);GOL A 998 (-4.9A);None;GOL A 998 (-4.6A)","0.40A","3sxrA-1zy4A:20.0","3sxrA-1zy4A:27.02"],["3SXR_A_1N1A1_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",10,"LEU X  17;VAL X  25;ALA X  37;MET X  58;VAL X  67;ILE X  80;THR X  82;TYR X  84;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);None;None;None;STU X 902 (-4.1A);STU X 902 (-4.6A);STU X 902 (-3.5A);STU X 902 (-4.4A)","0.53A","3sxrA-2dq7X:34.2","3sxrA-2dq7X:41.90"],["3SXR_A_1N1A1_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;VAL A 323;ILE A 336;THR A 338;TYR A 340;GLY A 344;LEU A 393","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;H8H A 534 ( 4.5A);H8H A 534 (-3.1A);H8H A 534 (-4.3A);H8H A 534 (-3.3A);H8H A 534 (-4.5A)","0.47A","3sxrA-2h8hA:30.8","3sxrA-2h8hA:24.11"],["3SXR_A_1N1A1_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;VAL A 323;ILE A 336;THR A 338;GLY A 344;LEU A 393","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 (-4.4A)","0.61A","3sxrA-2hckA:30.6","3sxrA-2hckA:32.43"],["3SXR_A_1N1A1_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 643;ALA A 659;MET A 682;ILE A 705;THR A 707;GLY A 713;LEU A 761","ADP A 400 ( 4.4A);ADP A 400 (-3.2A);None;None;ADP A 400 (-4.7A);ADP A 400 ( 4.2A);ADP A 400 ( 4.7A)","0.66A","3sxrA-2henA:31.6","3sxrA-2henA:36.71"],["3SXR_A_1N1A1_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",9,"LEU A 251;VAL A 259;ALA A 271;MET A 292;VAL A 301;ILE A 314;THR A 316;GLY A 322;LEU A 371","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 ( 3.8A);None;1BM A 499 (-3.9A);1BM A 499 (-3.2A);1BM A 499 (-3.5A);1BM A 499 (-4.4A)","0.47A","3sxrA-2hk5A:34.7","3sxrA-2hk5A:41.43"],["3SXR_A_1N1A1_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",9,"LEU A 248;VAL A 256;ALA A 269;MET A 290;VAL A 299;ILE A 313;THR A 315;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.2A);GIN A 600 (-4.6A);GIN A 600 (-3.8A);GIN A 600 (-3.4A);None;GIN A 600 (-4.7A)","0.65A","3sxrA-2hz0A:32.2","3sxrA-2hz0A:41.24"],["3SXR_A_1N1A1_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",7,"VAL A 436;ALA A 452;MET A 475;VAL A 484;ILE A 497;GLY A 505;LEU A 553","4ST A1687 ( 4.8A);4ST A1687 (-3.3A);None;None;None;4ST A1687 (-3.2A);4ST A1687 (-4.4A)","0.62A","3sxrA-2j0jA:31.2","3sxrA-2j0jA:18.66"],["3SXR_A_1N1A1_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",7,"VAL A 436;ALA A 452;MET A 475;VAL A 484;ILE A 497;GLY A 505;LEU A 553","BII A1687 ( 4.7A);BII A1687 (-3.5A);None;None;None;BII A1687 (-3.6A);BII A1687 (-4.2A)","0.55A","3sxrA-2jkmA:31.4","3sxrA-2jkmA:37.63"],["3SXR_A_1N1A1_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"ALA A 271;MET A 292;VAL A 301;ILE A 314;THR A 316;TYR A 318;GLY A 322;LEU A 371","1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);None;1N8 A 501 ( 4.6A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.58A","3sxrA-2og8A:31.0","3sxrA-2og8A:44.74"],["3SXR_A_1N1A1_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;VAL A 259;ALA A 271;MET A 292;VAL A 301;ILE A 314;THR A 316;TYR A 318","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);None;1N8 A 501 ( 4.6A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A)","0.52A","3sxrA-2og8A:31.0","3sxrA-2og8A:44.74"],["3SXR_A_1N1A1_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;ALA A 614;MET A 637;VAL A 647;THR A 663;TYR A 665;LEU A 785","None","0.59A","3sxrA-2ogvA:28.2","3sxrA-2ogvA:35.33"],["3SXR_A_1N1A1_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;ALA A 614;VAL A 647;THR A 663;TYR A 665;GLY A 669;LEU A 785","None","0.47A","3sxrA-2ogvA:28.2","3sxrA-2ogvA:35.33"],["3SXR_A_1N1A1_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ALA A 515;MET A 538;TYR A 566;GLY A 570;LEU A 633","None","0.51A","3sxrA-2psqA:32.1","3sxrA-2psqA:31.45"],["3SXR_A_1N1A1_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;MET A 674;ILE A 697;THR A 699;GLY A 705;LEU A 753","BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;None;None;None;None","0.66A","3sxrA-2qobA:32.1","3sxrA-2qobA:32.36"],["3SXR_A_1N1A1_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",8,"VAL A 689;ALA A 705;MET A 728;ILE A 751;THR A 753;TYR A 755;GLY A 759;LEU A 807","None","0.53A","3sxrA-2r2pA:33.6","3sxrA-2r2pA:35.59"],["3SXR_A_1N1A1_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",7,"LEU A 724;VAL A 732;ALA A 749;VAL A 781;THR A 796;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 ( 4.7A);GW7 A   1 (-4.0A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.68A","3sxrA-2r4bA:29.3","3sxrA-2r4bA:33.65"],["3SXR_A_1N1A1_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",8,"VAL A 635;ALA A 651;MET A 674;ILE A 697;THR A 699;TYR A 701;GLY A 705;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-3.9A);Q9G A1898 ( 4.6A);Q9G A1898 (-3.5A);Q9G A1898 (-4.8A);Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.53A","3sxrA-2xyuA:32.1","3sxrA-2xyuA:37.01"],["3SXR_A_1N1A1_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;MET A 674;ILE A 697;THR A 699;TYR A 701;SER A 763","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-3.9A);Q9G A1898 ( 4.6A);Q9G A1898 (-3.5A);Q9G A1898 (-4.8A);Q9G A1898 (-3.2A)","0.65A","3sxrA-2xyuA:32.1","3sxrA-2xyuA:37.01"],["3SXR_A_1N1A1_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1002;VAL A1010;ALA A1028;MET A1051;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A)","0.37A","3sxrA-2z8cA:30.6","3sxrA-2z8cA:37.83"],["3SXR_A_1N1A1_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",9,"LEU A 253;VAL A 261;ALA A 273;MET A 294;VAL A 303;ILE A 317;THR A 319;GLY A 325;LEU A 374","None","0.63A","3sxrA-2zv7A:33.9","3sxrA-2zv7A:43.32"],["3SXR_A_1N1A1_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ALA A 515;MET A 538;TYR A 566;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;M33 A1996 ( 4.7A);M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.30A","3sxrA-3b2tA:31.9","3sxrA-3b2tA:36.77"],["3SXR_A_1N1A1_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",9,"VAL A 209;ALA A 220;MET A 240;VAL A 249;ILE A 264;THR A 266;TYR A 268;GLY A 272;LEU A 321","None","0.53A","3sxrA-3d7uA:32.8","3sxrA-3d7uA:42.59"],["3SXR_A_1N1A1_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",7,"LEU A 431;VAL A 439;ALA A 455;VAL A 487;ILE A 500;GLY A 508;LEU A 556","AGS A 999 ( 4.4A);AGS A 999 (-4.6A);AGS A 999 (-3.6A);None;None;None;AGS A 999 (-4.5A)","0.68A","3sxrA-3fzpA:30.8","3sxrA-3fzpA:37.55"],["3SXR_A_1N1A1_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 833;VAL A 841;ALA A 859;VAL A 892;TYR A 911;GLY A 915;LEU A1029","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 ( 4.7A);8ST A2001 (-4.9A);None;None","0.64A","3sxrA-3hngA:29.0","3sxrA-3hngA:33.06"],["3SXR_A_1N1A1_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",7,"LEU A 696;VAL A 704;VAL A 753;THR A 768;TYR A 770;GLY A 774;LEU A 822","ANP A   1 (-4.4A);ANP A   1 (-3.9A);None;ANP A   1 ( 4.8A);ANP A   1 (-4.3A);ANP A   1 ( 4.9A);ANP A   1 (-4.7A)","0.48A","3sxrA-3kexA:27.6","3sxrA-3kexA:31.58"],["3SXR_A_1N1A1_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;ILE A 711;THR A 713;TYR A 715;GLY A 719;LEU A 767","None;None;None;None;GOL A 403 (-4.1A);GOL A 403 (-3.4A);None","0.64A","3sxrA-3kulA:33.8","3sxrA-3kulA:35.19"],["3SXR_A_1N1A1_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;MET A 688;THR A 713;TYR A 715;GLY A 719;LEU A 767","None;None;None;None;GOL A 403 (-4.1A);GOL A 403 (-3.4A);None","0.59A","3sxrA-3kulA:33.8","3sxrA-3kulA:35.19"],["3SXR_A_1N1A1_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"VAL A 218;ALA A 229;THR A 279;TYR A 281;GLY A 285;LEU A 339","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);LDN A   1 (-3.8A);LDN A   1 ( 4.8A);LDN A   1 (-3.3A);LDN A   1 (-4.5A)","0.31A","3sxrA-3mdyA:26.1","3sxrA-3mdyA:27.73"],["3SXR_A_1N1A1_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",7,"LEU A  88;VAL A  96;ALA A 109;MET A 134;TYR A 161;GLY A 165;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);None;None;None;None","0.66A","3sxrA-3nuuA:25.1","3sxrA-3nuuA:26.19"],["3SXR_A_1N1A1_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"LEU A 726;VAL A 734;ALA A 751;THR A 798;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.1A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.43A","3sxrA-3pp0A:30.8","3sxrA-3pp0A:30.27"],["3SXR_A_1N1A1_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",8,"VAL A 565;ALA A 576;MET A 600;VAL A 609;THR A 625;TYR A 627;GLY A 631;LEU A 683","STU A   1 (-4.9A);STU A   1 (-3.3A);None;None;STU A   1 (-4.1A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 (-4.3A)","0.48A","3sxrA-3ppzA:32.0","3sxrA-3ppzA:34.15"],["3SXR_A_1N1A1_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",8,"VAL A 565;ALA A 576;VAL A 609;ILE A 623;THR A 625;TYR A 627;GLY A 631;LEU A 683","STU A   1 (-4.9A);STU A   1 (-3.3A);None;None;STU A   1 (-4.1A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 (-4.3A)","0.47A","3sxrA-3ppzA:32.0","3sxrA-3ppzA:34.15"],["3SXR_A_1N1A1_1","3s95","Homo sapiens","LIM DOMAIN KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 345;MET A 388;THR A 413;TYR A 415;ILE A 416;GLY A 419;LEU A 467","STU A   1 (-3.8A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-4.3A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.61A","3sxrA-3s95A:25.6","3sxrA-3s95A:30.13"],["3SXR_A_1N1A1_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",12,"LEU A 423;VAL A 431;ALA A 443;MET A 464;VAL A 473;ILE A 487;THR A 489;TYR A 491;ILE A 492;GLY A 495;LEU A 543;SER A 553","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;PP2 A   1 (-3.6A);PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 (-4.1A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A);PP2 A   1 (-3.5A)","0.38A","3sxrA-3sxsA:42.4","3sxrA-3sxsA:100.00"],["3SXR_A_1N1A1_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;MET A 535;TYR A 563;GLY A 567;LEU A 630","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-4.7A);07J A   1 (-3.7A);07J A   1 ( 4.4A)","0.63A","3sxrA-3tt0A:28.8","3sxrA-3tt0A:31.41"],["3SXR_A_1N1A1_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 544;VAL A 552;ALA A 570;VAL A 601;TYR A 619;GLY A 623;LEU A 686","0F4 A 902 ( 4.2A);None;0F4 A 902 (-3.2A);None;0F4 A 902 (-4.2A);0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.34A","3sxrA-3v5qA:30.9","3sxrA-3v5qA:37.54"],["3SXR_A_1N1A1_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"LEU A  75;VAL A  83;ALA A  96;VAL A 128;ILE A 142;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-4.2A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.52A","3sxrA-3wigA:23.3","3sxrA-3wigA:25.72"],["3SXR_A_1N1A1_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 840;VAL A 848;ALA A 866;VAL A 899;GLY A 922;LEU A1035","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);None;LEV A1201 (-3.6A);LEV A1201 (-4.8A)","0.38A","3sxrA-3wzdA:29.8","3sxrA-3wzdA:36.16"],["3SXR_A_1N1A1_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",7,"LEU A1951;VAL A1959;ALA A1978;MET A2001;ILE A2024;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.80A","3sxrA-3zbfA:25.2","3sxrA-3zbfA:39.93"],["3SXR_A_1N1A1_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 633;ALA A 649;MET A 672;ILE A 695;THR A 697;GLY A 703;LEU A 751","None","0.53A","3sxrA-3zfxA:33.0","3sxrA-3zfxA:38.31"],["3SXR_A_1N1A1_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",6,"LEU A  83;VAL A  91;ALA A 104;TYR A 156;GLY A 160;LEU A 207","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);VX6 A 500 (-4.2A);VX6 A 500 (-3.3A);VX6 A 500 (-4.6A)","0.42A","3sxrA-4af3A:20.8","3sxrA-4af3A:23.51"],["3SXR_A_1N1A1_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 560;VAL A 568;ALA A 586;VAL A 617;TYR A 635;GLY A 639;LEU A 699","LTI A1839 ( 4.2A);None;LTI A1839 (-3.3A);None;LTI A1839 (-4.7A);LTI A1839 (-3.4A);LTI A1839 (-4.2A)","0.43A","3sxrA-4at3A:30.2","3sxrA-4at3A:36.79"],["3SXR_A_1N1A1_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"VAL A 105;ALA A 121;MET A 144;ILE A 167;THR A 169;GLY A 175;LEU A 223","30K A1365 ( 4.6A);30K A1365 (-3.2A);None;None;30K A1365 (-3.8A);30K A1365 (-3.5A);30K A1365 (-4.5A)","0.47A","3sxrA-4aw5A:32.1","3sxrA-4aw5A:35.96"],["3SXR_A_1N1A1_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",7,"LEU A  42;VAL A  50;ALA A  63;VAL A  94;ILE A 108;GLY A 116;LEU A 164","XZN A1317 (-3.6A);XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-4.4A);XZN A1317 (-4.4A);XZN A1317 ( 3.7A);XZN A1317 (-4.7A)","0.64A","3sxrA-4bc6A:22.5","3sxrA-4bc6A:29.69"],["3SXR_A_1N1A1_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 663;VAL A 671;ALA A 684;VAL A 721;TYR A 739;GLY A 743;LEU A 789","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;None;None;AGS A1985 (-4.8A)","0.48A","3sxrA-4crsA:24.4","3sxrA-4crsA:25.85"],["3SXR_A_1N1A1_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 575;ALA A 588;VAL A 620;ILE A 634;GLY A 642;LEU A 690","GUI A 901 (-4.5A);GUI A 901 (-3.4A);None;None;GUI A 901 (-3.5A);GUI A 901 (-4.3A)","0.39A","3sxrA-4e93A:33.6","3sxrA-4e93A:37.35"],["3SXR_A_1N1A1_1","4eqm","Staphylococcus aureus","PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  16;VAL A  24;ALA A  37;VAL A  71;TYR A  89;ILE A  90;LEU A 140","ANP A 300 (-4.7A);ANP A 300 ( 4.7A);ANP A 300 ( 3.8A);None;ANP A 300 (-4.3A);ANP A 300 (-4.8A);ANP A 300 (-4.7A)","0.64A","3sxrA-4eqmA:23.4","3sxrA-4eqmA:24.83"],["3SXR_A_1N1A1_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;MET A 424;VAL A 433;GLY A 454;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);None;None;0SB A 701 (-3.5A);0SB A 701 (-4.4A)","0.59A","3sxrA-4f4pA:31.9","3sxrA-4f4pA:38.63"],["3SXR_A_1N1A1_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1122;VAL A1130;ALA A1148;VAL A1180;ILE A1194;GLY A1202;LEU A1256","0UV A1501 (-3.8A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 ( 4.9A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A)","0.44A","3sxrA-4fodA:30.4","3sxrA-4fodA:33.83"],["3SXR_A_1N1A1_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"LEU A 828;VAL A 836;ALA A 853;VAL A 884;TYR A 904;GLY A 908;LEU A 956","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);None;19S A1201 (-4.7A);19S A1201 ( 3.8A);19S A1201 (-4.5A)","0.44A","3sxrA-4hviA:30.9","3sxrA-4hviA:32.14"],["3SXR_A_1N1A1_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.40A","3sxrA-4hzsA:16.7","3sxrA-4hzsA:39.86"],["3SXR_A_1N1A1_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.43A","3sxrA-4id7A:33.1","3sxrA-4id7A:39.21"],["3SXR_A_1N1A1_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;VAL A 323;ILE A 336;TYR A 340;GLY A 344;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);None;0J9 A 601 (-4.4A);0J9 A 601 ( 4.7A);0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A)","0.52A","3sxrA-4k11A:30.4","3sxrA-4k11A:29.67"],["3SXR_A_1N1A1_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"LEU A 478;VAL A 486;ALA A 506;MET A 529;TYR A 557;GLY A 561;LEU A 624","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);None;None;ACP A 801 ( 4.6A);ACP A 801 (-4.4A)","0.49A","3sxrA-4k33A:32.6","3sxrA-4k33A:34.88"],["3SXR_A_1N1A1_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",8,"LEU A  33;VAL A  41;ALA A  54;MET A  74;VAL A  83;ILE A  97;TYR A 101;GLY A 105","GOL A 404 ( 3.6A);GOL A 404 (-4.5A);GOL A 404 ( 3.1A);None;GOL A 403 (-4.1A);None;GOL A 404 ( 4.9A);GOL A 404 (-3.6A)","0.54A","3sxrA-4lg4A:25.4","3sxrA-4lg4A:29.93"],["3SXR_A_1N1A1_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;MET A 314;VAL A 323;ILE A 336;TYR A 340;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 ( 3.6A);VGG A 601 ( 4.8A);VGG A 601 (-4.2A);VGG A 601 ( 4.0A);VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.56A","3sxrA-4lggA:29.3","3sxrA-4lggA:43.70"],["3SXR_A_1N1A1_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"LEU A  46;ALA A  67;MET A  89;VAL A  99;THR A 123;GLY A 128;LEU A 180","SIN A 401 ( 3.9A);SIN A 401 ( 3.7A);None;None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.77A","3sxrA-4o38A:20.5","3sxrA-4o38A:26.11"],["3SXR_A_1N1A1_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"LEU A  46;VAL A  54;ALA A  67;VAL A  99;THR A 123;GLY A 128;LEU A 180","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.47A","3sxrA-4o38A:20.5","3sxrA-4o38A:26.11"],["3SXR_A_1N1A1_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 627;VAL A 635;ALA A 648;VAL A 685;TYR A 703;GLY A 707;LEU A 753","None","0.57A","3sxrA-4otdA:25.1","3sxrA-4otdA:26.55"],["3SXR_A_1N1A1_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 627;ALA A 644;ILE A 690;THR A 692;TYR A 694;GLY A 698;LEU A 746","None","0.57A","3sxrA-4p2kA:33.4","3sxrA-4p2kA:38.36"],["3SXR_A_1N1A1_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 627;ALA A 644;MET A 667;ILE A 690;THR A 692;TYR A 694;SER A 756","None","0.55A","3sxrA-4p2kA:33.4","3sxrA-4p2kA:38.36"],["3SXR_A_1N1A1_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);None;P30 A1001 (-4.1A);P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.38A","3sxrA-4rt7A:30.2","3sxrA-4rt7A:32.32"],["3SXR_A_1N1A1_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",10,"LEU A  14;VAL A  22;ALA A  35;MET A  56;VAL A  65;ILE A  79;THR A  81;TYR A  83;GLY A  87;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.53A","3sxrA-4ueuA:33.7","3sxrA-4ueuA:52.36"],["3SXR_A_1N1A1_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  52;VAL A  60;ALA A  72;MET A  94;VAL A 104;GLY A 132;LEU A 183","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;None;KSA A 405 (-3.5A);KSA A 405 (-4.6A)","0.60A","3sxrA-4wsqA:24.8","3sxrA-4wsqA:27.73"],["3SXR_A_1N1A1_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  52;VAL A  60;ALA A  72;VAL A 104;ILE A 124;GLY A 132;LEU A 183","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;None;KSA A 405 (-3.5A);KSA A 405 (-4.6A)","0.44A","3sxrA-4wsqA:24.8","3sxrA-4wsqA:27.73"],["3SXR_A_1N1A1_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.57A","3sxrA-4xeyB:33.4","3sxrA-4xeyB:30.88"],["3SXR_A_1N1A1_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"LEU B 267;VAL B 275;ALA B 288;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.44A","3sxrA-4xeyB:33.4","3sxrA-4xeyB:30.88"],["3SXR_A_1N1A1_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.83A","3sxrA-4xi2A:32.0","3sxrA-4xi2A:43.03"],["3SXR_A_1N1A1_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;SER A 538","None","0.69A","3sxrA-4xi2A:32.0","3sxrA-4xi2A:43.03"],["3SXR_A_1N1A1_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.5A);None;P30 A1001 ( 4.4A);P30 A1001 (-3.5A);P30 A1001 (-4.3A)","0.52A","3sxrA-4xufA:29.7","3sxrA-4xufA:39.67"],["3SXR_A_1N1A1_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",9,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);None;None;746 A 702 (-3.7A);746 A 702 (-4.4A);746 A 702 (-3.6A);746 A 702 (-4.4A)","0.41A","3sxrA-4y93A:32.9","3sxrA-4y93A:40.85"],["3SXR_A_1N1A1_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"VAL A 477;ALA A 488;ILE A 537;THR A 539;TYR A 541;LEU A 595","None;4CV A 801 (-3.5A);None;4CV A 801 (-2.8A);4CV A 801 (-3.9A);4CV A 801 (-4.4A)","0.39A","3sxrA-4yffA:26.0","3sxrA-4yffA:27.44"],["3SXR_A_1N1A1_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;MET A 535;TYR A 563;GLY A 567;LEU A 630","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);EDO A1766 (-3.5A);38O A1769 (-4.2A);38O A1769 (-3.4A);38O A1769 (-4.6A)","0.54A","3sxrA-5a46A:29.1","3sxrA-5a46A:32.62"],["3SXR_A_1N1A1_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;VAL A 911;ALA A 928;TYR A 980;GLY A 984;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);5U3 A1200 (-4.5A);5U3 A1200 (-3.2A);5U3 A1200 (-4.4A)","0.26A","3sxrA-5f1zA:29.8","3sxrA-5f1zA:33.44"],["3SXR_A_1N1A1_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",9,"LEU A 599;VAL A 607;ALA A 625;MET A 648;VAL A 658;THR A 674;TYR A 676;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-3.4A);748 A1001 ( 4.8A);748 A1001 (-3.2A);748 A1001 (-4.0A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.65A","3sxrA-5grnA:30.1","3sxrA-5grnA:35.77"],["3SXR_A_1N1A1_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",9,"LEU A 599;VAL A 607;ALA A 625;VAL A 658;ILE A 672;THR A 674;TYR A 676;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 ( 4.8A);748 A1001 (-3.9A);748 A1001 (-3.2A);748 A1001 (-4.0A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.56A","3sxrA-5grnA:30.1","3sxrA-5grnA:35.77"],["3SXR_A_1N1A1_1","5gz8","Mus musculus","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",8,"VAL A  94;ALA A 105;VAL A 134;ILE A 146;THR A 148;TYR A 150;GLY A 154;LEU A 215","None","0.55A","3sxrA-5gz8A:20.8","3sxrA-5gz8A:25.15"],["3SXR_A_1N1A1_1","5gza","Danio rerio","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",7,"VAL A  93;ALA A 104;VAL A 133;THR A 147;TYR A 149;GLY A 153;LEU A 214","ADP A 401 (-4.4A);ADP A 401 (-3.2A);None;ADP A 401 ( 4.8A);ADP A 401 ( 4.8A);ADP A 401 ( 4.1A);ADP A 401 (-4.4A)","0.45A","3sxrA-5gzaA:20.3","3sxrA-5gzaA:25.00"],["3SXR_A_1N1A1_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  57;VAL A  65;ALA A  77;ILE A 128;TYR A 132;GLY A 136;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);None;IDV A 401 (-3.5A);IDV A 401 (-3.4A);IDV A 401 (-4.4A)","0.39A","3sxrA-5i3oA:24.7","3sxrA-5i3oA:27.92"],["3SXR_A_1N1A1_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",8,"LEU A  57;VAL A  65;ALA A  77;MET A  99;VAL A 109;TYR A 132;GLY A 136;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);None;None;IDV A 401 (-3.5A);IDV A 401 (-3.4A);IDV A 401 (-4.4A)","0.46A","3sxrA-5i3oA:24.7","3sxrA-5i3oA:27.92"],["3SXR_A_1N1A1_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"VAL A  30;ALA A  43;MET A  65;VAL A  74;ILE A  88;GLY A  96;LEU A 143","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;None;None;6G2 A 901 (-3.6A);6G2 A 901 (-4.7A)","0.56A","3sxrA-5j5tA:22.8","3sxrA-5j5tA:24.09"],["3SXR_A_1N1A1_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",7,"VAL A 284;ALA A 297;MET A 319;VAL A 328;TYR A 346;GLY A 350;LEU A 396","IPW A 601 (-4.2A);IPW A 601 (-3.5A);IPW A 601 (-4.1A);None;IPW A 601 (-4.5A);IPW A 601 ( 3.8A);IPW A 601 (-4.5A)","0.46A","3sxrA-5kbrA:24.3","3sxrA-5kbrA:30.82"],["3SXR_A_1N1A1_1","5loh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE GREATWALL,SERINE\/THREONINE-PROTEIN KINASE GREATWALL","PF00069(Pkinase)",6,"VAL A  49;ALA A  60;VAL A  94;TYR A 112;GLY A 116;LEU A 163","None;STU A 901 (-3.3A);None;STU A 901 (-4.6A);STU A 901 (-3.5A);STU A 901 (-4.5A)","0.38A","3sxrA-5lohA:22.0","3sxrA-5lohA:26.15"],["3SXR_A_1N1A1_1","5vdk","Homo sapiens","WEE1-LIKE PROTEIN KINASE 2","PF00069(Pkinase)",6,"VAL A 226;ALA A 239;VAL A 273;ILE A 287;TYR A 291;GLY A 295","8X7 A 501 ( 4.5A);8X7 A 501 ( 3.7A);8X7 A 501 ( 4.6A);PO4 A 502 (-3.4A);8X7 A 501 (-4.2A);8X7 A 501 (-3.6A)","0.42A","3sxrA-5vdkA:17.8","3sxrA-5vdkA:20.60"],["3SXR_A_1N1A1_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",8,"LEU A  24;VAL A  32;ALA A  45;ILE A  93;THR A  95;TYR A  97;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.9A);9WS A 401 (-3.2A);None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.49A","3sxrA-5w5jA:24.0","3sxrA-5w5jA:28.84"],["3SXR_A_1N1A1_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",8,"LEU A 891;VAL A 899;ALA A 917;ILE A 961;THR A 963;TYR A 965;GLY A 969;LEU A1017","ANP A1201 (-4.1A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);None;ANP A1201 (-3.9A);ANP A1201 (-4.4A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A)","0.49A","3sxrA-5wnoA:27.9","3sxrA-5wnoA:14.90"],["3SXR_A_1N1A1_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",8,"LEU A  33;VAL A  41;ALA A  54;VAL A  83;ILE A  97;TYR A 101;GLY A 105;LEU A 153","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);None;None;ANP A 501 ( 4.2A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A)","0.56A","3sxrA-6ao5A:23.0","3sxrA-6ao5A:24.59"],["3SXR_A_1N1A1_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",6,"LEU A 881;VAL A 889;ALA A 906;VAL A 938;GLY A 962;LEU A1010","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.38A","3sxrA-6c7yA:30.7","3sxrA-6c7yA:15.24"],["3SXR_A_1N1A1_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",7,"LEU A 197;VAL A 205;ALA A 217;ILE A 262;THR A 264;GLY A 270;LEU A 319","FKY A9001 (-4.1A);FKY A9001 ( 4.6A);FKY A9001 (-3.3A);None;FKY A9001 (-3.0A);FKY A9001 (-3.3A);FKY A9001 ( 4.9A)","0.66A","3sxrA-6cz4A:30.1","3sxrA-6cz4A:17.34"],["3SXR_A_1N1A1_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",6,"VAL A 200;ALA A 211;VAL A 246;TYR A 264;GLY A 268;LEU A 318","CJT A 502 ( 4.8A);CJT A 502 (-3.4A);None;CJT A 502 (-4.5A);CJT A 502 ( 4.3A);CJT A 502 (-4.7A)","0.43A","3sxrA-6f3dA:25.3","3sxrA-6f3dA:17.65"],["3SXR_A_1N1A1_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",6,"LEU A 730;VAL A 738;ALA A 756;TYR A 806;GLY A 810;LEU A 881","ADN A1104 ( 4.0A);ADN A1104 (-4.4A);ADN A1104 (-3.4A);ADN A1104 ( 4.1A);ADN A1104 ( 3.8A);ADN A1104 (-4.3A)","0.40A","3sxrA-6fekA:31.9","3sxrA-6fekA:17.18"]]